DLL3 作为连接 NECC 恶性进展与免疫抑制的关键枢纽,其治疗意义经类器官-TIL 共培养系统验证
DLL3 serves as a pivotal hub bridging malignant progression and immunosuppression in NECC with therapeutic implications validated via the organoid-TIL
肿瘤细胞治疗研究
DISEASE HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov、CDE 与 ChiCTR 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
DLL3 serves as a pivotal hub bridging malignant progression and immunosuppression in NECC with therapeutic implications validated via the organoid-TIL
MEMBER ACCOUNT
登录成功会直接打开下一页。